AMN Healthcare Services (AMN)
(Delayed Data from NYSE)
$42.57 USD
-0.06 (-0.14%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $42.57 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$42.57 USD
-0.06 (-0.14%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $42.57 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
Here's Why You Should Retain CVS Health (CVS) Stock for Now
by Zacks Equity Research
Investors are optimistic about CVS Health (CVS), owing to consistent improvement in its consumer-centric digital solutions and raised guidance.
NuVasive (NUVA) Gets FDA Nod for Attrax Putty Expanded Use
by Zacks Equity Research
NuVasive's (NUVA) Attrax Putty is the first and only synthetic biologic to receive 510(k) indications for use in interbody fusions of the thoracolumbar spine.
Thermo Fisher (TMO) Completes Buyout of PeproTech for $1.85B
by Zacks Equity Research
Thermo Fisher's (TMO) recent acquisition will boost its capabilities to serve in the high-growth cell and gene therapy market.
Here's Why You Should Retain Baxter (BAX) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Baxter (BAX) due to its strong product portfolio.
AngioDynamics (ANGO) Q2 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
AngioDynamics (ANGO) registers strong revenue growth across the majority of its GBUs, as well as in domestic and international revenues in fiscal 2022 Q2.
Illumina (ILMN)-SomaLogic Ink Deal to Advance Proteomics
by Zacks Equity Research
Illumina's (ILMN) collaboration with SomaLogic will boost the fast-growing high throughput sector of the proteomics market to aid research in biology and disease.
Hologic's (HOLX) GAI Program to Include Aptima SARS-CoV-2 Assay
by Zacks Equity Research
The addition of Aptima SARS-CoV-2 assay to Hologic's (HOLX) Global Access Initiative is likely to improve its accessibility.
AMN Healthcare Services (AMN) Stock Moves -1.68%: What You Should Know
by Zacks Equity Research
In the latest trading session, AMN Healthcare Services (AMN) closed at $118.61, marking a -1.68% move from the previous day.
STERIS (STE) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Strong segmental performances are driving the top line for STERIS (STE).
3 Reasons to Retain Integer Holdings (ITGR) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Integer Holdings (ITGR) owing to its improving non-medical sales and solid foothold in the broader MedTech space.
Here's Why You Should Retain Phibro (PAHC) Stock for Now
by Zacks Equity Research
Investors are optimistic about Phibro (PAHC), given robust performance by its nutritional specialties and vaccine product lines.
Omnicell (OMCL) to Expand EnlivenHealth Division With New Buyout
by Zacks Equity Research
Omnicell's (OMCL) $82-million buyout of MarkeTouch Media is likely to expand its Advanced Services portfolio.
AMN Healthcare Services (AMN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
AMN Healthcare Services (AMN) closed the most recent trading day at $120.64, moving -0.13% from the previous trading session.
3 Reasons to Add Accuray (ARAY) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Accuray (ARAY) owing to its slew of software upgrades.
Fretting Over Market Volatility? Bet on These 4 Low-Beta Stocks
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. AMN Healthcare (AMN), Vista Outdoor (VSTO), Sensus Healthcare (SRTS) and Ameresco (AMRC) are well poised to gain.
Why Should You Hold Universal Health (UHS) in Your Portfolio?
by Zacks Equity Research
Riding high on strategic measures and a solid solvency level, Universal Health (UHS) holds prospects to reap benefits for investors.
3 Reasons to Add McKesson (MCK) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about McKesson (MCK) owing to its robust Biologics business.
Quidel's (QDEL) Antigen Tests Successful in Omicron Detection
by Zacks Equity Research
The success of Quidel's (QDEL) antigen tests against Omicron is expected to lead to better access to affordable COVID-19 testing.
Forget DaVita (DVA), Buy These 3 Lucrative Medical Care Stocks
by Trina Mukherjee
With stocks offering dialysis services, including DaVita (DVA), facing several issues, it would be prudent to invest in medical care and services stocks like DGX, AMN and CODX instead for 2022.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
PacBio's (PACB) New Surveillance Kit Successful Against Omicron
by Zacks Equity Research
PacBio's (PACB) latest surveillance kit is expected to aid public health entities to better answer critical questions about Omicron and its impacts.
Phillips' (PHG) Partner Base Expansion Drives Prospects
by Zacks Equity Research
Phillips (PHG) signed a long-term agreement with IJsselland Hospital to facilitate digitization and innovation in healthcare.
AMN Healthcare (AMN) Hits 52-Week High: What's Behind It?
by Zacks Equity Research
Investors are optimistic about AMN Healthcare's (AMN) broad array of services.
AMN Healthcare (AMN) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
AMN Healthcare (AMN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
AmerisourceBergen (ABC) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about AmerisourceBergen's (ABC) strength in its World Courier business.